SIC 2834 – Pharmaceutical Preparations
| Valuation | |
|---|---|
| Market Cap ($M) | 144.02 |
| Enterprise Value ($M) | 121.60 |
| Book Value ($M) | 21.19 |
| Book Value / Share | 0.32 |
| Price / Book | 6.80 |
| NCAV ($M) | 18.62 |
| NCAV / Share | 0.28 |
| Price / NCAV | 7.74 |
| Profitability (mra) | |
|---|---|
| Return on Invested Capital (ROIC) | -1.24 |
| Return on Assets (ROA) | -0.81 |
| Return on Equity (ROE) | -1.13 |
| Liquidity (mrq) | |
|---|---|
| Quick Ratio | 2.96 |
| Current Ratio | 3.31 |
| Balance Sheet (mrq) ($M) | |
|---|---|
| Current Assets | 28.18 |
| Assets | 30.75 |
| Liabilities | 9.56 |
| Debt | n/a |
| Equity | n/a |
| Income Statement (mra) ($M) | |
|---|---|
| Revenue | 0.00 |
| Operating Income | -31.11 |
| Net Income | -30.04 |
| Earnings Per Share Basic And Diluted | n/a |
| Earnings Per Share Diluted | n/a |
| Earnings Per Share Basic | n/a |
| Cash Flow Statement (mra) ($M) | |
|---|---|
| Cash From Operations | -26.77 |
| Cash from Investing | 14.49 |
| Cash from Financing | 11.82 |
(click for more detail) |
|
| File Date | Form | Activist 13D/G Investors | Ownership (%) |
Change (%) |
|---|---|---|---|---|
| 13G/A | Fmr Llc | 4.46 | 0.00 | |
| 13G | Ra Capital Management, L.p. | 9.50 | ||
| 13G | Deep Track Capital, LP | 9.99 | ||
| 13G | Vivo Opportunity Fund Holdings, L.P. | 7.70 | ||
| 13D/A | Growth Equity Opportunities V, LLC | 9.99 | 235.79 | |
| 13G | DAFNA Capital Management LLC | 5.49 | ||
| 13G/A | Victory Capital Management Inc | 5.71 | 35.91 | |
| 13G/A | Federated Hermes, Inc. | 19.90 | 3.83 |
| Top 13F Investors | Shares (1000) |
Change (%) |
Value ($1000) |
Change (%) |
|---|---|---|---|---|
(click for more detail) |
||||
| Date | Insider Trades | Code | Shares | Value |
|---|---|---|---|---|
(click for more detail) |
||||
| File Date | Form | SEC Filings |
|---|---|---|
| UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-K | ||
| UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q | ||
| UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q | ||
| UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q | ||
(click for more detail) |
||
| Short Volume | |||
|---|---|---|---|
| Market Date | Short Volume | Total Volume | Short Volume Ratio |
| 22,980 | 96,246 | 23.88 | |
| 26,148 | 34,420 | 75.97 | |
| 31,812 | 67,441 | 47.17 | |
| 21,317 | 47,227 | 45.14 | |
(click for more detail) |
|||
| Similar Companies | |
|---|---|
| RENB – Renovaro Inc. | REVB – Revelation Biosciences, Inc. |
| RGC – Regencell Bioscience Holdings Limited | RMTI – Rockwell Medical, Inc. |
| RNAZ – TransCode Therapeutics, Inc. |